Immobilized isomerous tumor vaccine and its preparing process

Abstract

An immobilized isomerous tumor vaccine with sure anticancer immunotherapeutic effect is disclosed, which is prepared by extracting from the cancer cells taken from different patients. It can generate the specific immune mechanism for preventing and dissolving cancers, convert the static lymphocytes to immunological lymphocytes and amplify immunological lymphocytes.

Description

technical field [0001] The invention relates to a medical preparation containing immune factors, in particular to a heterogeneous solidified antigen peptide tumor vaccine prepared by extracting whole cells of a certain allogeneic tumor (carcinoma, sarcoma) and its preparation method. Background technique [0002] It has been recognized in modern times that tumor is a genetic disease, but the basic research of which gene mutation or gene deletion is the cause of cell canceration has not yet formed a complete theory. Therefore, the research method of practical theory is more important in the method of tumor immunotherapy. [0003] At present, the anti-tumor immune biological agents in domestic and foreign literature reports can be roughly divided into the following categories: 1. Interleukins; 2. Interferon, immune ribonucleic acid; 3. Tumor necrosis factor; 4. Costimulatory molecular gene therapy; 5. Special virus gene therapy; 6. Interleukin-2 amplified Lack cell (LAK) ther...

AI Technical Summary

Problems solved by technology

The above various products and research results have reported curative effects on immune anti-cancer from animal experiments to clinical applications, but in fact it is difficult to repeat their stable effects, and they all have the following common deficiencies: 1. Immunological curative effect is inaccurate, and animal experiments are often effective, but clinical application efficacy is not obvious; 2. Clinical application often produces "high fever", unsafe toxic and side effects such as allergies, and even promotes cancer growth; 3. It is still difficult to establish a confirmed Specific anti-cancer immune function; 4. The preparation is expensive, and it is difficult to transform from the laboratory into industrial production; 5. More importantly, they are all limited to a certain "cloning, gene or factor" to study and solve tumor immunotherapy. Therefore, it is difficult to achieve the purpose of treatment. The reason is that the antigenicity of tumor cells is extremely weak, and it is the endogenous peptide product of polyclonal and multi-cancerous genes. Therefore, its mechanism needs to be explored and further studied.

Images